Foresite Capital Opportunity Management V’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Foresite Capital Opportunity Management V’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$9.67M	Hold	5,227,307	–	–	29.04%	1
2022 Q2	$16M	Hold	5,227,307	–	–	40.44%	1
2022 Q1	$37.7M	Hold	5,227,307	–	–	52.85%	1
2021 Q4	$85.6M	Buy	+5,227,307	New	+$60.8M	57.37%	1

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Foresite Capital Opportunity Management V's PRDS Position: Q3 2022 in Review

Foresite Capital Opportunity Management V held its Pardes Biosciences, Inc. Common Stock (PRDS) position steady in Q3 2022 at 5,227,307 shares worth $9.67M. The position accounts for 29.04% of the portfolio, ranked #1.

Foresite Capital Opportunity Management V first reported a position in PRDS in Q4 2021 and has held it in 4 quarters since. The position peaked at $85.6M in Q4 2021. 68 funds tracked by Wall St. Rank hold PRDS as of Q3 2022.

Foresite Capital Opportunity Management V held 5,227,307 shares of Pardes Biosciences, Inc. Common Stock worth $9.67M as of Q3 2022.
Foresite Capital Opportunity Management V left its Pardes Biosciences, Inc. Common Stock share count unchanged in Q3 2022.
Pardes Biosciences, Inc. Common Stock made up 29.04% of Foresite Capital Opportunity Management V's portfolio in Q3 2022, its #1 holding.
Foresite Capital Opportunity Management V first reported a position in Pardes Biosciences, Inc. Common Stock in Q4 2021 and has held it in 4 quarters since.
Foresite Capital Opportunity Management V's Pardes Biosciences, Inc. Common Stock position peaked at $85.6M in Q4 2021.
68 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2022.

Based on Foresite Capital Opportunity Management V's 13F filing for Q3 2022, filed 14 Nov 2022.